In a strategic move to solidify its presence in the rapidly evolving metabolic health sector, Roche has announced an exclusive licensing agreement with Hanmi Pharmaceutical for the development and commercialization of HM17321, a clinical-stage investigational therapy designed to address obesity while preserving muscle mass. The agreement, executed through Roche’s Genentech subsidiary, involves an upfront payment of $190 million, with Hanmi eligible to receive additional milestone payments totaling up to $2.3 billion, plus tiered royalties on future sales. This deal grants Roche global rights to the asset, excluding South Korea, where Hanmi retains its rights to the therapy.
The acquisition of HM17321 represents a critical pivot for Roche as it seeks to differentiate itself from market leaders Novo Nordisk and Eli Lilly. While current blockbuster GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonists such as Wegovy and Zepbound have demonstrated unprecedented efficacy in total weight reduction, they have also highlighted a significant clinical challenge: the concurrent loss of lean body mass. Clinical data suggest that up to 40% of weight lost through traditional incretin therapies can come from muscle tissue rather than fat, a side effect that can lead to physical weakness, metabolic slowdown, and increased risk of frailty, particularly in older populations.
The Science of Muscle Preservation: Understanding HM17321
HM17321 is a long-acting peptide analog of urocortin-2 (UCN2). Unlike existing obesity treatments that primarily target the gut-brain axis to suppress appetite, HM17321 targets the corticotropin-releasing factor type 2 (CRF2) receptors. These receptors are found in various tissues, including the central nervous system, but are notably prevalent in skeletal muscle.
The mechanism of action for HM17321 is dual-pronged. By activating CRF2 receptors in muscle tissue, the drug is designed to promote muscle hypertrophy (growth) and improve muscle function. Simultaneously, the activation of these receptors has been shown to influence systemic metabolism, facilitating the reduction of adipose tissue (fat). This "quality of weight loss" approach is becoming the next frontier in metabolic medicine, shifting the clinical focus from the number on the scale to the composition of the body.
Preclinical studies conducted by Hanmi Pharmaceutical have shown that HM17321 can effectively reduce body weight as a monotherapy. However, its potential as a combination therapy is perhaps its most compelling attribute. In animal models, the administration of HM17321 alongside GLP-1 receptor agonists resulted in synergistic weight loss while successfully mitigating the muscle atrophy typically observed with GLP-1 monotherapy.
Financial Terms and Developmental Chronology
The financial structure of the deal underscores the high stakes of the obesity market. The $190 million upfront payment provides Hanmi with immediate capital to fuel its broader R&D pipeline, while the $2.3 billion in potential milestones is contingent upon the achievement of specific clinical, regulatory, and commercial hurdles.
The development timeline for HM17321 is currently in its early clinical stages. Hanmi Pharmaceutical has already initiated a Phase 1 clinical trial, which is currently enrolling both healthy volunteers and individuals living with obesity. Under the terms of the agreement, Hanmi will remain responsible for the completion of this initial Phase 1 study. Following the conclusion of this phase, Genentech will assume full responsibility for the global clinical development, manufacturing, and commercialization of the drug.
This deal follows a series of high-profile acquisitions and partnerships by Roche as it aggressively rebuilds its metabolic pipeline. In late 2023, Roche acquired Carmot Therapeutics for $2.7 billion, gaining access to a portfolio of injectable and oral GLP-1/GIP agonists, including CT-388. Furthermore, Roche partnered with Zealand Pharma in a deal worth $1.65 billion upfront to develop petrelintide, a long-acting amylin analog. Like HM17321, petrelintide is aimed at improving the quality of weight loss and patient tolerability compared to existing treatments.
A Growing Competitive Landscape in Muscle-Sparing Therapies
Roche is not the only pharmaceutical giant looking beyond simple weight loss. The "muscle-sparing" sub-sector of the obesity market is becoming increasingly crowded as researchers recognize the long-term health implications of lean mass loss.
In early 2024, the Danish biotech firm Gubra announced the initiation of a Phase 1/2a study for GUB-UCN2, another urocortin-2 analog targeting the same CRF2 pathway as Hanmi’s candidate. Additionally, Regeneron Pharmaceuticals is exploring combinations of its myostatin-inhibiting antibodies, such as trevogrumab, with GLP-1 drugs to prevent muscle loss. Eli Lilly has also entered this space through its $1.9 billion acquisition of Versanis Bio, which brought in bimagrumab, a monoclonal antibody designed to block activin type II receptors to increase muscle mass while decreasing fat.
The entrance of Roche into the UCN2 space with a multi-billion dollar commitment signals a high level of confidence in the CRF2 receptor as a viable therapeutic target. By securing HM17321, Roche positions itself to offer a "cocktail" approach to obesity management, potentially combining its Carmot-derived incretins with Hanmi’s muscle-preserving peptide.
Official Responses and Strategic Vision
The leadership at both Roche and Hanmi has expressed optimism regarding the potential of this collaboration to redefine the standard of care for metabolic disorders. Boris Zaïtra, Head of Roche Corporate Business Development, emphasized that the acquisition is a cornerstone of the company’s broader strategy.
"By licensing this next-generation investigational therapy with first-in-class potential from Hanmi, Roche and Genentech will pursue a differentiated approach to selectively reduce fat mass while improving both muscle mass and muscle function," Zaïtra stated. "Our goal is to build a portfolio that meets the diverse needs of patients, moving beyond weight loss to address the holistic health of individuals with obesity, type 2 diabetes, and cardiovascular risks."
For Hanmi Pharmaceutical, the deal represents a significant validation of its proprietary peptide platform. Hanmi has a history of partnering with global pharmaceutical companies, having previously established and navigated complex agreements with Sanofi and Eli Lilly. The retention of rights in South Korea allows Hanmi to maintain a direct commercial presence in its home market while leveraging Roche’s global infrastructure for worldwide distribution.
Market Implications and the Future of Obesity Treatment
The global obesity market is projected by some analysts to reach $100 billion by 2030. As the market matures, the differentiation of products will become paramount. The first wave of treatments focused on efficacy (percentage of weight loss); the second wave is focusing on "quality of life" factors, including ease of administration (oral vs. injectable) and side-effect profiles (nausea and muscle loss).
The clinical implications of muscle preservation are particularly relevant for the treatment of "sarcopenic obesity"—a condition where an individual has high body fat alongside low muscle mass. This condition is prevalent in the elderly and is associated with a higher rate of mortality and disability. If HM17321 succeeds in clinical trials, it could become the preferred treatment for older patients or those with pre-existing mobility issues, for whom muscle loss would be catastrophic.
Furthermore, the potential for fixed-dose combinations (FDCs) could simplify treatment regimens. If Roche can successfully combine a GLP-1 agonist with a UCN2 analog in a single weekly injection, it would create a significant competitive advantage over companies offering separate therapies that require multiple administrations.
Chronology of Roche’s Metabolic Expansion
To understand the significance of the Hanmi deal, it is necessary to look at Roche’s rapid-fire expansion in the metabolic space over the last 18 months:
- December 2023: Roche acquires Carmot Therapeutics for $2.7 billion. This gave Roche CT-388 (a once-weekly dual GLP-1/GIP agonist) and CT-996 (a daily oral GLP-1).
- May 2024: Roche reports positive Phase 1b data for CT-388, showing significant weight loss in patients with type 2 diabetes, fueling optimism for its metabolic pipeline.
- July 2024: Roche enters into a major partnership with Zealand Pharma for petrelintide, an amylin receptor agonist, targeting weight loss with better tolerability and muscle preservation.
- September 2024: Roche announces the $2.5 billion licensing deal with Hanmi Pharmaceutical for HM17321, adding a first-in-class UCN2 analog to its portfolio.
This timeline demonstrates a clear pattern: Roche is systematically acquiring assets that cover every major biological pathway related to weight loss—incretins (GLP-1/GIP), amylin, and now urocortin (UCN2).
Conclusion and Outlook
The agreement between Roche and Hanmi Pharmaceutical marks a significant milestone in the shift toward "precision" metabolic medicine. As the medical community moves away from a one-size-fits-all approach to weight loss, the ability to tailor treatments to a patient’s specific physiological needs—such as the need to protect muscle mass—will become a primary driver of commercial success.
While HM17321 still faces the rigorous hurdles of Phase 2 and Phase 3 clinical testing, the underlying biology and preclinical results offer a promising path forward. For Roche, the deal is a high-stakes bet that the future of obesity therapy lies not just in making patients smaller, but in making them stronger. As the Phase 1 trial concludes and Genentech takes the reins, the industry will be watching closely to see if this urocortin-2 analog can deliver on the promise of healthy, sustainable weight management.
